Together with colleagues from the PDE4NPD Consortium, IOTA scientist Dr David Bailey has participated in the design and optimisation of new antiparasitic lead molecules targeting parasite phosphodiesterases. Read the full report of this work in the Journal of Medicinal Chemistry here, and more about IOTA’s phosphodiesterase drug discovery strategy here.